Wednesday, February 10, 2010, 7:30am EST - Canadian Markets open in 2 hours.
To create a watchlist or portfolio of shares, Sign-in or Register

AETERNA ZENTARIS COM NPV (AEZ.TO)

 On Feb 9: 0.87 CAD   0.00 (0.00%)  
MORE ON AEZ.TO
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
AETERNA ZENTARIS COM NPV (Toronto:AEZ.TO) Delayed quote dataEdit
Last Trade: 0.87 CAD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.87
Open: 0.92
Bid: 0.86
Ask: 0.91
1y Target Est: N/A
Day's Range: 0.86 - 0.92
52wk Range: 0.72 - 3.49
Volume: 29,443
Avg Vol (3m): 105,833
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A%)
AETERNA ZENTARIS COM NPV (AEZ.TO)
1d  5d  3m  6m  1y  2y  5y  max 
 Add AEZ.TO to Portfolio   Download Data

HEADLINES
• AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of
PRNewswire (Wed, Feb 3)
• Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of
CNW Group (Wed, Feb 3)
• Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo
CNW Group (Fri, Jan 29)
• AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macrogl
PRNewswire (Fri, Jan 29)
• Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer
PRNewswire (Wed, Jan 27)
• UPDATE - Spectrum to end development of enlarged-prostate drug
at Reuters (Wed, Jan 27)
• Liberty Analytics Co. Initiates Independent Research Coverage on AEterna Zentaris Inc.
GlobeNewswire (Tue, Jan 26)
• Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Cont
CNW Group (Mon, Jan 25)
• AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Con
PRNewswire (Mon, Jan 25)
• Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KR
PRNewswire (Mon, Jan 25)
More Headlines for AEZ.TO...
BUSINESS SUMMARY
No business summary available for AEZ.TO.


Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices